Copyright (c) 2018 AJC
This work is licensed under a Creative Commons Attribution 4.0 International License.
Scalable and Impurity-Free Process for Dasatinib: Src and BCR-Abl Inhibitor
Corresponding Author(s) : G. Buchappa
Asian Journal of Chemistry,
Vol. 30 No. 7 (2018): Vol 30 Issue 7
Abstract
An efficient, telescopic, impurity-free and scalable process for Bcr-Abl and Src family tyrosine kinase inhibitor for synthesis of Dasatinib with high yield and purity is described.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- J.S. Tokarski, J.A. Newitt, C.Y.J. Chang, J.D. Cheng, M. Wittekind, S.E. Kiefer, K. Kish, F.Y.F. Lee, R. Borzillerri, L.J. Lombardo, D. Xie, Y. Zhang and H.E. Klei, Cancer Res., 66, 5790 (2006); https://doi.org/10.1158/0008-5472.CAN-05-4187.
- A.I. Marcus, A.M. O’Brate, R.M. Buey, J. Zhou, S. Thomas, F.R. Khuri, J.M. Andreu, F. Díaz and P. Giannakakou, Cancer Res., 66, 8838 (2006); https://doi.org/10.1158/0008-5472.CAN-06-0699.
- A. Serrels, I.R.J. Macpherson, T.R.J. Evans, F.Y. Lee, E.A. Clark, O.J. Sansom, G.H. Ashton, M.C. Frame and V.G. Brunton, Mol. Cancer Ther., 5, 3014 (2006); https://doi.org/10.1158/1535-7163.MCT-06-0382.
- M. Talpaz, N.P. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, J. Cortes, S. O’Brien, C. Nicaise, E. Bleickardt, M.A. BlackwoodChirchir, V. Iyer, T.-T. Chen, F. Huang, A.P. Decillis and C.L. Sawyers, N. Engl. J. Med., 354, 2531 (2006); https://doi.org/10.1056/NEJMoa055229.
- Food and Drug Administration, Orphan Designations Pursuant to Section 526 of the Federal Food and Cosmetic Act as Amended by the Orphan Drug Act (P.L. 97-414), Rockville, MD; 21 March (2006).
- L.J. Lombardo, F.Y. Lee, P. Chen, D. Norris, J.C. Barrish, K. Behnia, S. Castaneda, L.A.M. Cornelius, J. Das, A.M. Doweyko, C. Fairchild, J.T. Hunt, I. Inigo, K. Johnston, A. Kamath, D. Kan, H. Klei, P. Marathe, S. Pang, R. Peterson, S. Pitt, G.L. Schieven, R.J. Schmidt, J. Tokarski, M.-L. Wen, J. Wityak and R.M. Borzilleri, J. Med. Chem., 47, 6658 (2004); https://doi.org/10.1021/jm049486a.
- R. Yan, H. Yang, W. Hou and Y. Xu, Synthesis Process of Dasatinib and Intermediate Thereof, Eur. Patent 2532662A1 (2012).
- A. Baruto, M. Gaboardi, M. Castaldi and G. Castaldi, Process and Intermediates for the Preparation of Dasatinib, Eur. Patent 2918584A1 (2015).
- J.S. Jaryal, M. Kapoor, S. Sathyanarayana, R.K. Thaper and M. Prasad, Process for the Preparation of Dasatinib and its Intermediates, US Patent 9365526B2 (2015).
- J. Das, R. Padmanabha, P. Chen, D.J. Norris, A.M.P. Doweyko, J.C. Barrish and J. Wityak, WO 062778 A1 (2000).
References
J.S. Tokarski, J.A. Newitt, C.Y.J. Chang, J.D. Cheng, M. Wittekind, S.E. Kiefer, K. Kish, F.Y.F. Lee, R. Borzillerri, L.J. Lombardo, D. Xie, Y. Zhang and H.E. Klei, Cancer Res., 66, 5790 (2006); https://doi.org/10.1158/0008-5472.CAN-05-4187.
A.I. Marcus, A.M. O’Brate, R.M. Buey, J. Zhou, S. Thomas, F.R. Khuri, J.M. Andreu, F. Díaz and P. Giannakakou, Cancer Res., 66, 8838 (2006); https://doi.org/10.1158/0008-5472.CAN-06-0699.
A. Serrels, I.R.J. Macpherson, T.R.J. Evans, F.Y. Lee, E.A. Clark, O.J. Sansom, G.H. Ashton, M.C. Frame and V.G. Brunton, Mol. Cancer Ther., 5, 3014 (2006); https://doi.org/10.1158/1535-7163.MCT-06-0382.
M. Talpaz, N.P. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, J. Cortes, S. O’Brien, C. Nicaise, E. Bleickardt, M.A. BlackwoodChirchir, V. Iyer, T.-T. Chen, F. Huang, A.P. Decillis and C.L. Sawyers, N. Engl. J. Med., 354, 2531 (2006); https://doi.org/10.1056/NEJMoa055229.
Food and Drug Administration, Orphan Designations Pursuant to Section 526 of the Federal Food and Cosmetic Act as Amended by the Orphan Drug Act (P.L. 97-414), Rockville, MD; 21 March (2006).
L.J. Lombardo, F.Y. Lee, P. Chen, D. Norris, J.C. Barrish, K. Behnia, S. Castaneda, L.A.M. Cornelius, J. Das, A.M. Doweyko, C. Fairchild, J.T. Hunt, I. Inigo, K. Johnston, A. Kamath, D. Kan, H. Klei, P. Marathe, S. Pang, R. Peterson, S. Pitt, G.L. Schieven, R.J. Schmidt, J. Tokarski, M.-L. Wen, J. Wityak and R.M. Borzilleri, J. Med. Chem., 47, 6658 (2004); https://doi.org/10.1021/jm049486a.
R. Yan, H. Yang, W. Hou and Y. Xu, Synthesis Process of Dasatinib and Intermediate Thereof, Eur. Patent 2532662A1 (2012).
A. Baruto, M. Gaboardi, M. Castaldi and G. Castaldi, Process and Intermediates for the Preparation of Dasatinib, Eur. Patent 2918584A1 (2015).
J.S. Jaryal, M. Kapoor, S. Sathyanarayana, R.K. Thaper and M. Prasad, Process for the Preparation of Dasatinib and its Intermediates, US Patent 9365526B2 (2015).
J. Das, R. Padmanabha, P. Chen, D.J. Norris, A.M.P. Doweyko, J.C. Barrish and J. Wityak, WO 062778 A1 (2000).